1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. Defence Therapeutics Inc.
  6. Company
    DTC   CA24463V1013

DEFENCE THERAPEUTICS INC.

(DTC)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensus 
Business Summary
Logo Defence Therapeutics Inc.
Defence Therapeutics Inc. is a Canada-based biotechnology company. The Company’s principal business activity is the development of a biological drug enhancer platform for biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company is engaged in developing the vaccines and antibody drug conjugates (ADC) products. Its Accum Technology platform provides drug delivery enhancements. The Company is focused on infectious disease and virus vaccine development by utilizing its platform for targeted drug delivery and treatments. Accum-T-DM1 is the Company’s product that is in preclinical stage.
Managers
Name Title Age Since
Sébastien Plouffe President, Chief Executive Officer & Director 48 -
P. Joseph Meagher Chief Financial Officer & Director 36 2020
Simon Beaudoin, Dr. Chief Technology & Science Officer 37 2017
Moutih Rafei, Dr. Director & VP-Research & Development 39 -
Carrie Cesarone Secretary 55 -
Members of the board
Name Title Age Since
Raimar Löbenberg, Dr. Chairman 55 -
Sarkis Meterissian, Dr. Independent Director 59 -
Sébastien Plouffe President, Chief Executive Officer & Director 48 -
P. Joseph Meagher Chief Financial Officer & Director 36 2020
Moutih Rafei, Dr. Director & VP-Research & Development 39 -
Riam Shammaa, Dr. Director - 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 36,014,674 33,828,674 93.9% 0 0.0% 93.9%
Shareholders
NameEquities%
Sébastien Plouffe 1,600,000 4.41%
P. Joseph Meagher 350,000 0.96%
Raimar Löbenberg 100,000 0.28%
Moutih Rafei 70,000 0.19%
Carrie Cesarone 66,000 0.18%
Riam Shammaa 0 -
Brand Portfolio
In partnership withAllbrands.markets
More brands of Defence Therapeutics Inc.